key: cord-0849037-ttq0tbty
authors: Pathoulas, James T.; Farah, Ronda S.; Fiessinger, Lori; Mansh, Matthew
title: An opportunity for improvement: iPLEDGE policy changes during the coronavirus pandemic
date: 2020-10-21
journal: Dermatol Ther
DOI: 10.1111/dth.14411
sha: 15d187d4d98a8784e44381566e37deeabdd67799
doc_id: 849037
cord_uid: ttq0tbty

nan

Dear Editor, iPLEDGE is a risk evaluation and mitigation strategy program created to reduce fetal exposure to isotretinoin due to its high risk of teratogenicity. However, iPLEDGE has failed to meet its primary aim, as there is a lack of evidence that the program reduces the incidence of fetal exposure to isotretinoin. 1 The iPLEDGE program has been additionally criticized for creating significant administrative burdens, causing delays and interruptions in isotretinoin therapy which disproportionately affect racial minorities and other socioeconomically disadvantaged groups. 2 iPLEDGE has historically required patients with reproductive potential to obtain monthly pregnancy tests at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. In response to the coronavirus disease 2019 (COVID-19) pandemic, iPLEDGE has begun permitting telemedicine visits and the use of home pregnancy testing during isotretinoin therapy. 3 These practice changes may increase access to isotretinoin therapy and help avoid delays or interruptions in therapy, but require increased provider education regarding at-home pregnancy tests and careful review of any changes occurring in pregnancy data if they are to be continued post COVID-19.

Home urine pregnancy tests have variable sensitivity and require users to accurately interpret results. iPLEDGE had required CLIAcertified laboratory pregnancy tests to detect serum human chorionic gonadotropin (hCG) at 25 mIU/mL, which is the same hCG detection threshold for most home urine pregnancy tests (Table 1) . However, independent evaluation of home pregnancy tests found that agreement between laboratory-determined and manufacturer-advertised accuracy ranged from less than 50% to greater than 90% by brand. Use of an accurate and reliable test can reduce error but all tests require user interpretation. 5 Digital home tests are preferred by users and may address interpretation errors, but are more expensive (Table 1) . 5 If use of home pregnancy tests during isotretinoin therapy is adopted post COVID-19, highly accurate and easily interpretable commercial tests will need to be identified along with guidelines for their use.

Despite challenges, home pregnancy testing is cost-effective and convenient. Patients report incurring indirect costs greater than $25 due to lost wages from missed work or childcare associated with inperson care required during isotretinoin therapy. 6 Common at-home pregnancy tests range from $0.30 to $6.99 per test (Table 1) and represent an opportunity to reduce the potential cost barrier associated with in-person visits and monitoring required by iPLEDGE. Home pregnancy testing lends physicians greater autonomy in individualizing testing for each patient. While high-risk laboratory anomalies prompting a change in isotretinoin treatment are rare and raise questions about the need for frequent in-person nonpregnancy laboratory monitoring, providers with concerns about the sensitivity of at-home pregnancy tests who elect to monitor metabolic labs could add on a periodic serum pregnancy test. 7 Others have suggested decreasing the frequency of routine pregnancy testing for patients with tubal ligation and/or those using long-acting reversible contraception, such as implantable or intrauterine devices. 2, 8, 9 Perhaps in this group of patients, it would be most appropriate to consider continued home pregnancy testing post COVID-19.

Our specialty should work with iPLEDGE administrators to study the impact of new policies, including rates of pregnancy and attributable birth defects, the gestational age at time of positive test, test type used, and modality of patient-provider communication among 

A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study

Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era

COVID-19) update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency

Sensitivity of over-the-counter pregnancy tests: comparison of utility and marketing messages

Comparison of analytical sensitivity and women's interpretation of home pregnancy tests

Personal burden of isotretinoin therapy and willingness to pay for electronic follow-up visits

Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis

Simplifying contraception requirements for iPLEDGE: a decision analysis

Isotretinoin, patient safety, and patient-centered care-time to reform iPLEDGE